Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
121-135 of 395
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
AudioAbstractsAre E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
Ryan Quigley
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Project Oncology®ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Updates in AML Care: Evolving ASH Guidelines for Older Adults
On the Frontlines of AML/ALLUpdates in AML Care: Evolving ASH Guidelines for Older Adults
Shelina Ramnarine, PhD
Mikkael A. Sekeres, MD, MS
Venetoclax and Palbociclib in AML: Exploring New Findings
On the Frontlines of AML/ALLVenetoclax and Palbociclib in AML: Exploring New Findings
Ryan Quigley
Jeffrey Tyner, PhD
Melissa Stewart, PhD
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
On the Frontlines of AML/ALLAdvancing Relapse Prediction in Pediatric AML Through Genomic MRD
Ryan Quigley
Amanda Winters, MD, PhD
How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
Project Oncology®How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
Alexandria May, PharmD, BCPS
Sunnie Kim, MD
- advertisement
Understanding the Growing Burden of Early-Onset CRC
On the Frontlines of Colorectal CancerUnderstanding the Growing Burden of Early-Onset CRC
Ryan Quigley
Christopher Cann, MD
Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerDecoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
Abirami Sivapiragasam
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
On the Frontlines of AML/ALLNeighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
Charles Turck, PharmD, BCPS, BCCCP
Lena Winestone, MD, MSHP
Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
Project Oncology®Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
Charles Turck, PharmD, BCPS, BCCCP
Kelly McCann, MD, PhD
Gregory Vidal, MD, PhD
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
AudioAbstractsImproving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
Ryan Quigley
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Project Oncology®Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
- advertisement
Cosibelimab Delivers Durable Responses in Advanced CSCC
Project Oncology®Cosibelimab Delivers Durable Responses in Advanced CSCC
Oncogenic Drivers in Never-Smokers with NSCLC
Project Oncology®Oncogenic Drivers in Never-Smokers with NSCLC
Apar Kishor Ganti, MD, MS
Expanding Molecular Testing in Community NSCLC Care
Project Oncology®Expanding Molecular Testing in Community NSCLC Care
Apar Kishor Ganti, MD, MS
